Erasmus University, Rotterdam

Atorvastatin showed a more favorable effect than other statins

Published in Biotech Law Weekly, November 11th, 2005

A recent population-based cohort study examined differences between statins on clinical endpoints.

According to investigators in the Netherlands, "Many studies have shown differences between statins based on surrogate endpoints, but few have studied differences in reaching clinical endpoints. [Our] study compares the risk of cardiovascular and cerebrovascular events between atorvastatin users and other statin users in daily general practice."

J.P. Dieleman and colleagues of Erasmus University in Rotterdam explained, "A cohort study was performed in the Integrated Primary Care Information project database, a longitudinal general practice research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2005-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry